Combined Checkpoint Inhibition and Chemotherapy: New Era of 1(st)-Line Treatment for Non-Small-Cell Lung Cancer

Platinum-based chemotherapy has long been the first-line treatment of choice for metastatic non-small-cell lung cancer (NSCLC) patients who lack targetable gene mutations. The arrival of checkpoint blockade has led to a vast shift in the treatment landscape of NSCLC. Among NSCLC patients with PD-L1...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chongkai, Kulkarni, Prakash, Salgia, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444295/
https://www.ncbi.nlm.nih.gov/pubmed/30976658
http://dx.doi.org/10.1016/j.omto.2019.02.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444295/
https://www.ncbi.nlm.nih.gov/pubmed/30976658
http://dx.doi.org/10.1016/j.omto.2019.02.001

Ejemplares similares